Resolving the daratumumab interference with blood compatibility testing.
about
Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myelomaMonoclonal antibodies targeting CD38 in hematological malignancies and beyondPhase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma.Systematic review and meta-analysis of the efficacy and safety of novel monoclonal antibodies for treatment of relapsed/refractory multiple myeloma.Daratumumab: First Global Approval.Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma.Novel Immunotherapies for Multiple Myeloma.Practical Approaches to the Management of Dual Refractory Multiple Myeloma.An update on the role of daratumumab in the treatment of multiple myeloma.Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.The safety of daratumumab for the treatment of multiple myeloma.Immunotherapy: A New Approach to Treating Multiple Myeloma with Daratumumab and Elotuzumab.Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma.New developments in the treatment of multiple myeloma - clinical utility of daratumumab.Daratumumab for the treatment of multiple myeloma.Practical approaches and costs for provisioning safe transfusions during anti-CD38 therapy.The Challenges of Daratumumab in Transfusion Medicine.Daratumumab, Elotuzumab, and the Development of Therapeutic Monoclonal Antibodies in Multiple Myeloma.Safety issues and management of toxicities associated with new treatments for multiple myeloma.Mass Spectrometry Approaches for Identification and Quantitation of Therapeutic Monoclonal Antibodies in the Clinical Laboratory.Therapy for Relapsed Multiple Myeloma: Guidelines From the Mayo Stratification for Myeloma and Risk-Adapted Therapy.International validation of a dithiothreitol (DTT)-based method to resolve the daratumumab interference with blood compatibility testing.Interference of daratumumab with pretransfusion testing, mimicking a high-titer, low avidity like antibody.Role of daratumumab in transfusion medicine: a must know entity.Long-term CD38 saturation by daratumumab interferes with diagnostic myeloma cell detection.Daratumumab: A Review in Relapsed and/or Refractory Multiple Myeloma.How do I work up pretransfusion samples containing anti-CD38?An evaluation of storage time for dithiothreitol-treated reagent cells.Immunotherapy Strategies Against Multiple Myeloma.Daratumumab (anti-CD38) induces loss of CD38 on red blood cells.Molecular immunohaematology round table discussions at the AABB Annual Meeting, Orlando 2016.Daratumumab: Dawn of a New Paradigm in Multiple Myeloma?Transfusion management for patients taking an anti-CD38 monoclonal antibody.Daratumumab for the Treatment of Multiple Myeloma.Best Practice for the Administration of Daratumumab in Multiple Myeloma: Australian Myeloma Nurse Expert Opinion.51. Jahrestagung der Deutschen Gesellschaft für Transfusionsmedizin und Immunhämatologie (DGTI), Lübeck, 19.-21. September 2018, Abstracts
P2860
Q26745919-8592ABF7-AD32-4072-AD31-FFC47E2CCB53Q26766718-09A9CFA9-314C-4665-AA2B-429E7693A15EQ33434683-2933915F-8E97-4ADC-BB51-67E52E0CAD42Q33441476-A245229E-A5D6-4DA6-BE18-9EADA1CA321AQ34507354-D852A539-9987-4F37-885B-5B87C80F062CQ37076421-FEA6974D-95B4-4AF8-8B91-48A1F665E11EQ38640444-1B114EC7-180A-4B0B-A811-D64ED4423601Q38742700-18B107E6-972A-47B1-BE37-0F042C666FDAQ38775700-D71068DC-5565-4C51-87E2-21DF02D30185Q38792725-979DA3FC-CC66-4CEA-9844-5BBD1C9D4E17Q38793959-9C8DEAEF-CE2D-4B08-B66F-E35FDF0FF35CQ38809499-FCDE760E-3095-485F-BA2A-89AC8E0FB77AQ38817467-33260C30-4BCE-4A5A-98BD-132F597DED7AQ38820002-CD62712D-7759-4C23-8C13-2687D444FC04Q38824538-5DB938E4-6B44-4003-B132-F57E44B86AA6Q38985014-B400F125-978F-4317-8C2A-D2A9B7EF08C1Q38994343-97FC2753-1078-41A0-AB90-19398B94A045Q38996881-7D6921D0-3C14-457D-834F-70FBE476FFDFQ39100317-52F077CD-74E3-4DE7-B56A-2BF9D00CFBB1Q39169309-FA9771E5-C161-4A25-B78F-061B89CFCF29Q39177792-F3C756D7-DEE9-4E72-BB18-2ABA7BC64F58Q39417506-C0973179-6F31-4AE9-8F42-7A7F49FBE45BQ42003178-D8663957-2398-43D3-AEBA-F8F6DEAF1DBDQ45719678-52660027-1FAC-4958-9184-0187A07AC4A4Q46173025-F6C32C2A-8757-494F-9B5F-FE5FDC62BE1FQ47614728-C7B80516-E121-4149-B84B-940448AA9BEFQ48187335-BE368915-6E43-481B-AB5C-B5CD1C796E54Q49860157-06E5E3B9-3383-40F2-9295-99447D53DF19Q49995864-4E5154B3-1862-498A-AE46-5BAA2C02F808Q50211747-D03CB8ED-C25A-4893-ACF3-2BDA26A8F7D9Q51412052-086028D0-724E-40E8-B52B-9B5095B9ED17Q55021985-0230A99D-1646-46EA-8F17-B0DB189315DCQ55261498-0EF4CD2F-D441-40EA-AB7E-D97E02509864Q55337411-FA2DD2B5-990A-4F1C-8565-64A075D53E73Q55392778-508125CC-64EB-4863-9B12-1FE5129C657CQ58721513-ADE9FB14-F673-4716-BB7A-9112803E7FDF
P2860
Resolving the daratumumab interference with blood compatibility testing.
description
2015 nî lūn-bûn
@nan
2015 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի մարտին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Resolving the daratumumab interference with blood compatibility testing.
@ast
Resolving the daratumumab interference with blood compatibility testing.
@en
Resolving the daratumumab interference with blood compatibility testing.
@nl
type
label
Resolving the daratumumab interference with blood compatibility testing.
@ast
Resolving the daratumumab interference with blood compatibility testing.
@en
Resolving the daratumumab interference with blood compatibility testing.
@nl
prefLabel
Resolving the daratumumab interference with blood compatibility testing.
@ast
Resolving the daratumumab interference with blood compatibility testing.
@en
Resolving the daratumumab interference with blood compatibility testing.
@nl
P2093
P2860
P356
P1433
P1476
Resolving the daratumumab interference with blood compatibility testing.
@en
P2093
Bjoern Chapuy
Claudia I Chapuy
Jacob P Laubach
Maria D Aguad
Parul Doshi
Paul G Richardson
Rachel T Nicholson
Richard M Kaufman
P2860
P304
P356
10.1111/TRF.13069
P433
P577
2015-03-12T00:00:00Z